At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,877 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating Baricitinib and Placebo for Rheumatoid Arthritis. Completed, enrolled 2,877 participants across 408 sites in 38 countries.
Detailed Summary
The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study. The study provides 7 years of additional treatment with baricitinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJun 2013
Primary CompletionNov 2020
TodayJul 2026
First PostedJun 24, 2013
Enrollment StartJun 27, 2013
Primary CompletionNov 12, 2020
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 13.0 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally